Opendata, web and dolomites

NEXTER SIGNED

Next generation eco-friendly, microbiome preserving and reduced resistance therapeutics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NEXTER project word cloud

Explore the words cloud of the NEXTER project. It provides you a very rough idea of what is the project "NEXTER" about.

unpredictable    bacteria    desperately    protecting    cells    pathogenic    strains    antimicrobial    escape    emergence    pseudomonas    least    drugs    protein    ribosomal    pathogens    hence    commercialization    capacity    amr    strategic    aureus    clinically    harm    attaching    distinction    health    beneficial    powerful    bacterial    mechanisms    biosynthesis    selectivity    lower    medicine    alongside    prevent    additional    causing    pharma    partnership    structural    revolutionary    contaminate    resistant    delivered    enterococcus    compounds    commercialize    synthetic    inhibit    primary    technological    designed    strategy    preserve    perfecting    company    species    antibiotic    ip    companies    selective    negligible    environmental    designing    strengthen    motifs    attempt    modern    chemical    ribosome    global    environment    dozes    human    decrease    antibiotics    degradable    innovative    microbiome    shown    plan    poc    resistance    network    outcome    rapid    moieties    drug    stop    pharmaceuticals    efforts    pathogen    contamination    spread    discovered   

Project "NEXTER" data sheet

The following table provides information about the project.

Coordinator
WEIZMANN INSTITUTE OF SCIENCE 

Organization address
address: HERZL STREET 234
city: REHOVOT
postcode: 7610001
website: www.weizmann.ac.il

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2019
 Duration (year-month-day) from 2019-07-01   to  2020-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    WEIZMANN INSTITUTE OF SCIENCE IL (REHOVOT) coordinator 150˙000.00

Map

 Project objective

The rapid emergence and spread of Multi-drug Antimicrobial Resistance (AMR), alongside the negligible efforts of the major pharmaceuticals companies in the development of new antibiotics, result in a major global concern of modern medicine. Moreover, the currently clinically used antibiotics contaminate the environment and may harm the human microbiome, causing unpredictable health concerns. We discovered that by targeting species-specific ribosome unique structural motifs, identified by us, using our designed degradable novel synthetic lead compounds, it is possible to inhibit protein biosynthesis in bacteria. Our approach should enable distinction between pathogenic and non-pathogenic bacteria and between bacterial and human ribosome. This drug selectivity should decrease resistance, preserve the beneficial microbiome and allow usage of lower antibiotics dozes. Furthermore, the designed degradable lead compounds should prevent additional environmental contamination. Hence, our approach allows designing innovative powerful selective antibiotics that escape the existing resistance mechanisms. Several of the primary designed compounds shown to stop the growth of the multi-resistant S. aureus human pathogen were delivered into the bacterial cells by attaching specific chemical moieties to them. In this PoC we plan to design similar compounds for other human pathogens, such as Enterococcus and Pseudomonas species, where revolutionary effective antibiotic drugs against their resistant strains is desperately needed. In addition to the technological PoC in this project, we will attempt pre-commercialization studies aiming at perfecting the commercialization strategy, protecting the IP and strengthen the network for best possible commercialization outcome. The general objective is to establish at least one strategic partnership with a pharma company which has the capacity to further test, develop and commercialize antibiotics that exploit ribosomal novel unique targets.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEXTER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEXTER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

Resonances (2019)

Resonances and Zeta Functions in Smooth Ergodic Theory and Geometry

Read More  

Aware (2019)

Aiding Antibiotic Development with Deep Analysis of Resistance Evolution

Read More  

CARBYNE (2020)

New carbon reactivity rules for molecular editing

Read More